Bacterial Toxins and Immune System

A special issue of Toxins (ISSN 2072-6651). This special issue belongs to the section "Bacterial Toxins".

Deadline for manuscript submissions: closed (31 March 2026) | Viewed by 608

Special Issue Editors


E-Mail Website
Guest Editor
CIM-CID, ANA Futura Laboratory, Department of Medicine Huddinge, Karolinska Institutet, 141 52 Stockholm, Sweden
Interests: AMR; toxin–antitoxin; persistence; MDR; tolerance

E-Mail Website
Guest Editor
Institute of Experimental and Clinical Pharmacology, Toxicology and Pharmacology of Natural Products, Ulm University Medical Center, 89081 Ulm, Germany
Interests: actin; bacterial protein toxins; macrophages; rho-gtpases; cellular uptake and intracellular membrane transport of bacterial toxins; interaction of bacterial toxins with host cell chaperones; bacterial toxins as molecular trojan horses for drug delivery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Bacterial toxin release and its complex interactions with the immune system are overlooked problems in the human healthcare system. A key concern is that while antibiotics are essential for treating bacterial infections, certain classes can paradoxically trigger the release of potent toxins, worsening disease progression and contributing to toxic shock syndromes caused by pathogens such as Staphylococcus aureus, Streptococcus pyogenes, and Escherichia coli. Despite advances in antimicrobial therapies, effective therapeutic options for neutralizing these molecules once in systemic circulation remain scarce. Additionally, growing evidence suggests that some bacterial toxins, though not directly toxic, can modulate host–pathogen interactions in ways that promote bacterial survival. These factors may increase antibiotic tolerance and have been linked to higher relapse rates in chronic or recurrent infections.

This Special Issue focuses on the complex interplay between bacterial toxins and the immune system, highlighting both classical cytotoxic effects and emerging roles in infection persistence. It invites contributions that investigate toxin-mediated immune modulation, mechanisms of antibiotic-induced toxin release, and novel strategies for therapeutic intervention.

Dr. Itziar Chapartegui-González
Prof. Dr. Holger Barth
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • toxic shock
  • tolerance
  • bacterial toxin
  • immunomodulation
  • toxin neutralization
  • relapse

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

15 pages, 1574 KB  
Review
The Battle Against Pertussis: Discovery of Endogenous Human Proteins and Peptides as Toxin-Inhibitors
by Stefanie Lietz and Holger Barth
Toxins 2026, 18(5), 208; https://doi.org/10.3390/toxins18050208 - 29 Apr 2026
Viewed by 236
Abstract
The life-threatening disease pertussis, also known as whooping cough, is caused by a complex interplay of several virulence factors produced by the bacterium Bordetella (B.) pertussis. These include the AB-type protein toxin pertussis toxin (PT), the main causative agent of [...] Read more.
The life-threatening disease pertussis, also known as whooping cough, is caused by a complex interplay of several virulence factors produced by the bacterium Bordetella (B.) pertussis. These include the AB-type protein toxin pertussis toxin (PT), the main causative agent of pertussis. After infection with B. pertussis, PT is released and binds to its human target cells, which internalize PT. The enzyme subunit of PT is then taken up into the cytosol, where it catalyzes the ADP-ribosylation of the α-subunit of inhibitory GTP-binding proteins from the Gαi type. This ultimately leads to the development of the characteristic clinical symptoms associated with pertussis. Pertussis is a vaccine-preventable but highly infectious respiratory disease, and especially younger children are prone to develop severe pertussis. Despite the vaccination, over the past few years, increasing case numbers have been reported globally. Moreover, treatment options are strongly limited to antibiotics and symptomatic treatment. Therefore, novel therapies against toxin-mediated diseases are urgently required, while AB-type toxins such as PT are promising pharmacological targets to combat these associated diseases. To identify novel pharmacological inhibitors for AB-type toxins, huge potential lies within the human proteome/peptidome. Endogenous protein or peptide inhibitors for bacterial toxins might have evolved as part of the innate immunity and are awaited to be discovered. The scientific community is committed to identify potential candidates through targeted screening or explorative hypothesis-driven approaches. This review summarizes the recent efforts in the identification and characterization of the human body’s own proteins and peptides that inhibit PT. PT-inhibiting peptides were found by unbiased screening of peptide libraries from human hemofiltrate or hypothesis-driven evaluation, and PT-neutralizing mechanisms were discovered in cell-based approaches. The identification of endogenous peptides and proteins, e.g., defensins and α1-antitrypsin, as potent inhibitors of PT paves the way towards the development of novel therapeutic options against pertussis. Full article
(This article belongs to the Special Issue Bacterial Toxins and Immune System)
Show Figures

Graphical abstract

Back to TopTop